Our cohort shows a mixture of plausible incidence of high risk breast cancer patients (Table 1: TNBC 27% and HER2-positive 33%), offering comparable distributions of these molecular subtypes to the RCB validation cohorts (HER2 pos. This evidence concerns the gene ERBB2 and breast cancer.